I-Pembrolizumab Ivunyelwe eShayina ye-HCC Engasuswa Ngomuthi Ngokuhlanganiswa ne-Lenvatinib ne-TACE

Muva nje, i-Merck & Co., Inc. (Merck) imemezele ukuthi i-PD-1 inhibitor yayo, i-pembrolizumab, ivunyelwe yi-National Medical Products Administration (NMPA) yaseShayina ukuze isetshenziswe kanye ne-lenvatinib kanye ne-transarterial chemoembolization (TACE) ekwelapheni iziguli ezine-carcinoma yesibindi engasuswanga, engasabalali.

Ukuvunyelwa kwalesi sibonakaliso esisha kusekelwe kudatha evela kuvivinyo lwezokwelapha lwe-LeAP-012 lweSigaba III. Kulolu cwaningo lweSigaba III olunezikhungo eziningi, olungahleliwe, olungaboni kabili, (LEAP-012), iziguli ezingu-480 zabhaliswa futhi zabelwa ngokungahleliwe ukuthi zithole i-lenvatinib kanye ne-TACE kanye ne-pembrolizumab (n=237) noma i-TACE kanye ne-dual placebo (n=243).

Imiphumela ibonise ukuthi ukusinda okuphakathi kokusinda okungenawo ama-progression (PFS) kwakuyizinyanga ezingu-14.6 eqenjini le-lenvatinib kanye ne-TACE kanye ne-pembrolizumab, uma kuqhathaniswa nezinyanga ezingu-10.0 eqenjini le-placebo. Amazinga okusinda okuphelele kwezinyanga ezingu-24 (OS) ayengu-75% kanye no-69%, ngokulandelana.

I-Lenvatinibiyi-kinase inhibitor esetshenziselwa ukwelapha izinhlobo ezithile zomdlavuza. Ama-Kinase inhibitors angama-enzyme inhibitor avimba isenzo se-protein kinase eyodwa noma ngaphezulu.

I-Pembrolizumab iyi-antibody ye-monoclonal IgG4 kappa eyenziwe umuntu eqondiswe ebusweni beseli lomuntu i-PD-1 (i-programmed death receptor-1) kuma-lymphocyte. I-PD-1 receptor inikeza "indawo yokuhlola amasosha omzimba" ebalulekile, esiza ukuvimbela isimiso somzimba sokuzivikela ekuzihlaseleni. Izinhlobo ezithile zezimila zine-PD-L1 ephezulu (i-programmed death receptor ligand-1). Ezinye izinhlobo zezimila zisebenzisa ukumelana nokuzivikela komzimba okuguquguqukayo lapho zithatha khona i-physiology yemvelo yokungeniswa kwe-PD-L1 (ukuvikelwa komonakalo obangelwa amasosha omzimba ezifweni) bese ziyivumelanisa nezimpendulo zokulwa nesimila. Lapho i-PD-L1 ihlangana ne-PD-1, umsebenzi weseli le-T uyavinjelwa; i-pembrolizumab ivimba ukwakheka kwe-PD-1: PDL-1 complex okuvumela ukubulawa okuthuthukisiwe okubangelwa amasosha omzimba.

Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.

Inombolo yocingo: 4008803716

Email：myimmnet@163.com